Table 1.
Characteristics of patients and at-home episodes
| Patients, n | 105 |
| Episodes, n | 204 |
| Median age, years (range) | 63 (20–92) |
| Female, n (%) | 50 (47%) |
| Diagnosis, n (%) | |
| MM | 35 (33%) |
| AML | 27 (26%) |
| NHL | 16 (15%) |
| MDS | 15 (14%) |
| ALL | 5 (5%) |
| Others | 7 (7%) |
| Program, episodes (%) | |
| Admission avoidance programs | |
| At home autologous HSCT | 9 (5%) |
| At home consolidation in acute leukemia | 3 (1.5%) |
| Monitoring and electrolyte replacement (early discharge) | 43 (21%) |
| Antimicrobial drugs delivery | 16 (8%) |
| Venetoclax dose ramp-up | 4 (2%) |
| Day-hospital avoidance programs | |
| Azacitidine | 83 (40%) |
| Bortezomib | 34 (16.5%) |
| Carfilzomib | 12 (6%) |
| Re-admissions, n (%) | |
| SARS-CoV-2 related pneumonia | 4 (2%) |
| Other causes | 24 (12%) |
| Febrile neutropenia | 7 |
| Progression of underlying disease | 4 |
| Other infections | 8 |
| Other | 5 |
ALL acute lymphoid leukemia, AML acute myeloid leukemia, HSCT hematopoietic stem cell transplantation, HL Hodgkin lymphoma, MM multiple myeloma, MDS Myelodysplastic syndrome, NHL non-Hodgkin lymphoma